Get the Stockscreener App
17.08
0.59%
0.10
Pre-market:
17.40
0.32
+1.87%
Moonlake Immunotherapeutics stock is traded at $17.08, with a volume of 1.07M.
It is up +0.59% in the last 24 hours and down -5.90% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$16.98
Open:
$16.92
24h Volume:
1.07M
Relative Volume:
0.56
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-4.8442
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
-8.37%
1M Performance:
-5.90%
6M Performance:
+84.05%
1Y Performance:
-50.89%
1-Day Range:
$16.51
$17.39
1-Week Range:
$15.77
$18.32
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
17.08 | 1.23B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
BVF's departure from MoonLake suggests a shift towards high-beta rebalancing as institutions remain divided in their perspectives - Bitget
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
MLTX SEC FilingsMoonLake Immunotherapeutics 10-K, 10-Q, 8-K Forms - stocktitan.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake Immunotherapeutics (MLTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa - finance.yahoo.com
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment - TipRanks
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
BVF-linked MoonLake (MLTX) holder trims stake by 3.75M shares - stocktitan.net
MoonLake (MLTX) holder BVF sells shares but keeps 22.3% stake - stocktitan.net
MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8%Here's Why - MarketBeat
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - msn.com
Form 144 | MoonLake Immunotherapeutics(MLTX.US) 10% Stockholder Proposes to Sell 63.49 Million in Common Stocks - Moomoo
Affiliate sale notice: 3,750,000 shares proposed (NASDAQ: MLTX) - stocktitan.net
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics Jumps 9.6% During the Day Amid Positive Developments and Analyst Rating Increases - Bitget
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%Here's What Happened - MarketBeat
MoonLake’s lead asset shows durability in late-stage HS studies - finance.yahoo.com
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook - Investing.com
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves - simplywall.st
Research Analysts Issue Forecasts for MLTX Q1 Earnings - MarketBeat
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - Stock Traders Daily
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data - uk.investing.com
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - news.futunn.com
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results - The Clinical Trial Vanguard
MLTX Bounces on Week 40 Trial Data—Is This a Setup for a Gamma Squeeze Before H2 2026 BLA Deadline? - Bitget
MoonLake Immunotherapeutics (MLTX) Is Up 6.5% After Strong Week 40 Sonelokimab HS Data Release – Has The Bull Case Changed? - simplywall.st
AAD26: MoonLake, Incyte highlight deepening responses in long-term HS readouts - FirstWord Pharma
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial - TipRanks
Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa - Dermatology Times
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) An - Bitget
MoonLake Immunotherapeutics Reports Positive Week 40 Results from Phase 3 VELA Trials of Sonelokimab in Moderate-to-Severe Hidradenitis Suppurativa - Quiver Quantitative
Skin disease trial shows 62% response at 40 weeks, no new safety signals - stocktitan.net
MoonLake Immunotherapeutics (MLTX) price target increased by 35.37% to 30.19 - MSN
Earnings Risk: What is the earnings history of MoonLake ImmunotherapeuticsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
Buy Signal: What analysts say about MoonLake Immunotherapeutics stock2026 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):